Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Legend Reports Positive Results for CAR-T as Multiple Myeloma Therapy

publication date: Jun 6, 2023

Legend Biotech, a Nanjing-New Jersey CAR-T company, announced positive results from a US Phase III trial of its lead drug, cilta-cel, as an earlier treatment for multiple myeloma. The trial showed cilta-cel reduced disease progression by 74% compared to standard treatment in a trial that enrolled patients who had previously received one to three prior therapies. Cilta-cel is a BCMA autologous T-cell drug that shocked the world in 2017 with near 100% efficacy in multiple myeloma. It is already approved in China, the US and EU, though only after as many as four earlier treatment rounds. More details....

Stock Symbol: (NASDAQ: LEGN)

Share this with colleagues:  



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital